A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer
Shun Lu, Li Lü, Yi Luo et al. · Journal of Thoracic Oncology · 2015
Cited by 43 works. doi:10.1097/jto.0000000000000343 Open-access PDF
Authors
- Shun Lu
- Li Lü
- Yi Luo
- Li Zhang
- Gang Wu
- Zhiwei Chen
- Cheng Huang
- Shuliang Guo
- Yiping Zhang
- Xiangqun Song
- Yongfeng Yu
- Caicun Zhou
- Wei Li
- Meilin Liao
- Baolan Li
- Li‐Yan Xu
- Ping Chen
- Chunhong Hu
- Chengping Hu
References
- Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer
- Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base.
- Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124
- Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial
- Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732
- Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501
- Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study—CALGB 30504 (Alliance)
- [Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients].
- A randomized phase III study of irinotecan and cisplatin (CP) versus etoposide and cisplatin (EP) in extensive-disease small-cell lung cancer (ED-SCLC): Japan Clinical Oncology Group Study (JCOG 9511)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer